With $150M and a new NASH discovery deal with Gilead, AI star Daphne Koller has set out to change the drug R&D world
Daphne Koller spent the last year quietly putting together one of the biggest plays in biopharma AI. And backed by some of the deepest pockets in biotech, she’s now marking a key turning point for her fledgling startup insitro by forming a fresh R&D alliance with Gilead.
Basic subscription required
Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.